Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Doyen

Showing results (71-80 of 75) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 75 results.
Leukemia|June 24, 2000
Phase I/II study of 2-chloro-2'-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphomaE Van Den Neste, I Louviaux, J L Michaux, et al.
British Journal of Haematology|November 25, 1998
VAD or VMBCP in multiple myeloma refractory to or relapsing after cyclophosphamide-prednisone therapy (protocol MY 85)P Mineur, J F Ménard, X Le Loët, et al.
Acta Clinica Belgica|December 8, 2011
Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in BelgiumM Delforge, A Michiels, C Doyen, et al.
Acta Clinica Belgica|October 20, 2010
The Belgian 2010 consensus recommendations for the treatment of multiple myelomaR Schots, M Delforge, M André, et al.
Leukemia|July 13, 2007
Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trialsP Moreau, M Attal, F Garban, et al.
Pageof 8

Showing results (71-80 of 75) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 75 results.
Leukemia|June 24, 2000
Phase I/II study of 2-chloro-2'-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphomaE Van Den Neste, I Louviaux, J L Michaux, et al.
British Journal of Haematology|November 25, 1998
VAD or VMBCP in multiple myeloma refractory to or relapsing after cyclophosphamide-prednisone therapy (protocol MY 85)P Mineur, J F Ménard, X Le Loët, et al.
Acta Clinica Belgica|December 8, 2011
Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in BelgiumM Delforge, A Michiels, C Doyen, et al.
Acta Clinica Belgica|October 20, 2010
The Belgian 2010 consensus recommendations for the treatment of multiple myelomaR Schots, M Delforge, M André, et al.
Leukemia|July 13, 2007
Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trialsP Moreau, M Attal, F Garban, et al.
Pageof 8